Does Tradjenta (linagliptin) cause bullous pemphigus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Does Tradjenta Cause Bullous Pemphigoid?

Yes, Tradjenta (linagliptin) can cause bullous pemphigoid, and this is a recognized serious adverse effect that requires immediate discontinuation of the medication. 1

FDA-Recognized Association

The FDA drug label for Tradjenta explicitly warns about bullous pemphigoid as a serious adverse reaction. In the CARMELINA trial, bullous pemphigoid occurred in 7 patients (0.2%) treated with linagliptin compared to none in the placebo group, with 3 of these patients requiring hospitalization. 1 The FDA mandates that if bullous pemphigoid is suspected, Tradjenta should be discontinued immediately and the patient referred to a dermatologist for diagnosis and appropriate treatment. 1

Clinical Evidence and Risk Profile

Recent prospective case-control studies demonstrate that linagliptin specifically carries a strong association with bullous pemphigoid, distinguishing it from other DPP-4 inhibitors like sitagliptin which did not show comparable risk. 2 This is critical for clinical decision-making when selecting diabetes medications in elderly patients.

Key Clinical Features of Linagliptin-Associated BP:

  • Distinctive presentation: Patients often present with BP180-NC16A/BP230 seronegativity and milder, sometimes noninflammatory disease 2
  • Rapid onset: Median time from drug initiation to BP onset is approximately 3 months (range 1-12 months) 3
  • Severe disease potential: Despite sometimes milder presentations, severe cases requiring hospitalization occur, including complications like sepsis and endocarditis from secondary bacterial infections 4
  • Shorter disease duration: When the drug is discontinued, disease and follow-up duration tend to be shorter compared to idiopathic BP 3

What to Look For

Patients should be monitored for:

  • Development of blisters or erosions on skin 1
  • Pruritic vesiculobullous eruptions involving trunk, extremities, and intertriginous regions 5
  • Tense bullae with erosions and crusted plaques 5

Management Algorithm

  1. Immediate discontinuation of linagliptin upon suspicion of bullous pemphigoid 1
  2. Dermatology referral for confirmatory diagnosis (histopathology showing subepidermal blister with eosinophils; direct immunofluorescence showing linear C3 and IgG at basement membrane) 5
  3. Initiate treatment with topical or systemic immunosuppressive therapy (typically corticosteroids) 1
  4. Monitor for secondary infection, particularly in patients with prosthetic heart valves or other high-risk features, as superinfection can lead to endocarditis 4

Important Clinical Considerations

Co-medication risk factors: Patients taking angiotensin receptor blockers (ARBs) and statins alongside linagliptin may have higher risk of developing bullous pemphigoid. 3 This combination is common in diabetic patients with cardiovascular disease, making vigilance essential.

Alternative DPP-4 inhibitor: If a DPP-4 inhibitor is still needed, sitagliptin may be preferred in elderly patients as it has not demonstrated the same level of BP risk as linagliptin. 2

Diagnostic challenges: Some linagliptin-associated BP cases are BP180-NC16A/BP230 seronegative, which can delay diagnosis. Using BP180-ectodomain-based assays improves diagnostic performance in these patients. 2

Prognosis After Discontinuation

Most patients show progressive improvement and complete cessation of new blister formation after linagliptin discontinuation and initiation of appropriate immunosuppressive therapy. 5 However, approximately 50% of drug-induced pemphigus cases may continue despite drug withdrawal, requiring management similar to idiopathic disease. 6

References

Related Questions

In a diabetic patient who has been taking a DPP‑4 inhibitor (gliptin) for one year, can the drug still trigger bullous pemphigoid, or should other potential causes and medications be evaluated?
What are the indications for computed tomography (CT) scanning?
A patient in good general condition presents with sudden abdominal distension and pain radiating to the back; what is the best initial management?
What is the recommended curative multimodal treatment approach for an aggressively invasive esophageal carcinoma in a medically fit patient?
Can alcohol intake cause vomiting?
I have developed skin changes on the upper thigh near the knee and experience proximal leg weakness when rising from a chair that improves after walking or taking acetaminophen; what is the likely diagnosis and what laboratory, imaging, and initial treatment work‑up should I pursue?
What is the recommended polio vaccination schedule for adults, including initial inactivated polio vaccine series, booster timing, and management of severe vaccine allergies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.